AUG 2 1 2001 &

0300

PTO/SB/92 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
perwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

#3

## Certificate of Mailing under 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:

**Box DD** 

Hon. Assistant Commissioner for Assistant Commissioner for Patents Washington, D.C. 20231

on August 16, 2001

Date

Ellen M. Godfrey

Ellen M. Holfren
Signature

Type or printed name of person signing Certificate

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

Information Disclosure Statement form 1449 for USSN 09/899,29 Information Disclosure Statement Cover Letter for USSN 09/899,29



## PATENT APPLICATION

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN THE APPLICATION OF:

Shunag Liu et al.

CASE NO.: PH-7176

SERIAL NO.: 09/899,629

GROUP ART UNIT: Unknown

FILED: July 5, 2001

EXAMINER: Unknown

FOR: STABLE RADIOPHARMACEUTICAL COMPOSITIONS AND METHODS FOR

PREPARATION THEREOF

Wilmington, Delaware DATE: August 16, 2001

## INFORMATION DISCLOSURE STATEMENT

Box DD

Hon. Commissioner of Patents and Trademarks Washington, D.C. 20231

Sir:

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b). Copies of each of the references listed on the attached Form PTO-1449 are enclosed herewith.

- (XX) In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, no additional fee is required.
- () In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, therefore:
  - ( ) Certification in Accordance with §1.97(e) is set forth below.
  - ( ) The fee of \$240.00 as set forth in \$1.17(p) is attached.
- () In accordance with §1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311 but before the payment of the Issue Fee, therefore included are: Certification in Accordance with §1.97(e); Petition Requesting Consideration of the Information Disclosure Statement; and the fee of \$130.00 as set forth in §1.17(i)(1). Please charge any deficiency or credit any overpayment to Deposit Account No. 04-1928.

There are no listed references which are not in the English language or do not contain an

English language abstract.

Peter L. Dolan

Agent for Applicants Registration No. 46,307

Telephone 302-992-4528